IP Library Granted Patent US 8,685,731
Granted Patent B2
US 8,685,731 · App. 13/707,115 · Granted Apr 1, 2014

Process for the culturing of cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,685,731
App. No.
13/707,115
Granted
Apr 1, 2014
Kind
B2
Abstract

The invention relates to a process for the coloring of cells, preferably E1-immortalized HER cells, more preferably PER.C6 cells in a reactor in suspension in a cell culture medium, wherein the cells produce a biological substance, preferably an antibody, wherein at least one cell culture medium component is fed to the cell culture and wherein the cell culture comprising the cells, the biological substance and cell culture medium is circulated over a separation system and wherein the separation system separates the biological substance from substances having a lower molecular weight than the biological substance and wherein the biological substance is retained in or fed back into the reactor. Preferably part of the substances of lower molecular weight is continuously removed from the cell culture.

Claims (22)

1. Process for the culturing of cells in a reactor in suspension in a cell culture medium, comprising:

circulating a cell culture through a separation system, wherein the cell culture comprises eukaryotic cells, a biological substance produced by the cells, and a cell culture medium, wherein at least one cell culture medium component is fed to the cell culture;

wherein the cell culture is circulated through the separation system in a tangential flow;

wherein the separation system comprises a filter having a pore size with a molecular weight cut-off of at least 30 kDa, to separate the biological substance from substances having a lower molecular weight than the biological substance; and

wherein the biological substance is retained in or fed back into the reactor.

2. Process according to claim 1 , wherein the filter has a pore size with a molecular weight cut-off of at most 100 kDa.

3. Process according to claim 1 , wherein the filter has a pore size with a molecular weight cut-off of at most 50 kDa and the biological substance is an immunoglobulin G (IgG).

4. Process according to claim 1 wherein the eukaryotic cells have a viable cell density of at least 50×10 6 cells/ml and the concentration of the biological substance is at least 5 g/l.

5. Process according to claim 1 , wherein the eukaryotic cells are mammalian cells.

6. Process according to claim 5 , wherein the mammalian cells are selected from the group consisting of Chinese hamster ovary (CHO) cells, hybridomas, baby hamster kidney (BHK) cells, myeloma cells, human cells, or mouse cells.

7. Process according to claim 5 , wherein the mammalian cells are CHO cells.

8. Process according to claim 1 , wherein the cells have a cell viability of at least 98%.

9. Process according to claim 2 wherein the eukaryotic cells have a viable cell density of at least 50×10 6 cells/ml and the concentration of the biological substance is at least 5 g/l.

10. Process according to claim 2 , wherein the eukaryotic cells are mammalian cells.

11. Process according to claim 10 , wherein the mammalian cells are selected from the group consisting of Chinese hamster ovary (CHO) cells, hybridomas, baby hamster kidney (BHK) cells, myeloma cells, human cells, or mouse cells.

12. Process according to claim 10 , wherein the mammalian cells are CHO cells.

13. Process according to claim 3 , wherein the cells have a cell viability of at least 98%.

14. Process according to claim 3 wherein the eukaryotic cells have a viable cell density of at least 50×10 6 cells/ml and the concentration of the biological substance is at least 5 g/l.

15. Process according to claim 3 , wherein the eukaryotic cells are mammalian cells.

16. Process according to claim 15 , wherein the mammalian cells are selected from the group consisting of Chinese hamster ovary (CHO) cells, hybridomas, baby hamster kidney (BHK) cells, myeloma cells, human cells, or mouse cells.

17. Process according to claim 15 , wherein the mammalian cells are CHO cells.

18. Process according to claim 3 , wherein the cells have a cell viability of at least 98%.

Assignments (6)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE ADDRESS PREVIOUSLY RECORDED AT REEL: 033972 FRAME: 0269. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jan 25, 2016
From: DSM IP ASSETS B.V.
To: DPX HOLDINGS B.V.
Reel/Frame 037585/0052 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2014
From: DSM IP ASSETS B.V.
To: JLL/DELTA DUTCH NEWCO B.V.
Reel/Frame 034282/0574 →
CHANGE OF NAME Recorded Dec 1, 2014
From: JLL/DELTA DUTCH NEWCO B.V.
To: DPX HOLDINGS B.V.
Reel/Frame 034500/0795 →
CHANGE OF ADDRESS Recorded Dec 1, 2014
From: DPX HOLDINGS B.V.
To: DPX HOLDINGS B.V.
Reel/Frame 034500/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 12, 2014
From: DSM IP ASSETS B.V.
To: DPX HOLDINGS B.V.
Reel/Frame 033972/0269 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 12, 2012
From: ZIJLSTRA, G. M.; HOF, R. P.; SCHILDER, J.
To: DSM IP ASSETS B.V.
Reel/Frame 029456/0325 →